Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
66 Results for "
score
" in MedChemExpress (MCE) Product Catalog:
Products (66)
66 Results for "score" in MCE Product Catalog:
23
Research Areas:
Itacitinib (INCB039110) is an orally active selective inhibitor of JAK1 with an IC50 value of 2 nM for human JAK1. Itacitinib inhibits IFN-γ-mediated phosphorylation of STAT1 and downstream pro-inflammatory signaling pathways. Itacitinib reduces the frequency and number of splenic neutrophils in mouse models, downregulates the levels of pro-inflammatory cytokines and chemokines, and inhibits pro-inflammatory gene expression pathways. Itacitinib improves survival rate and clinical scores in mouse models of hemophagocytic lymphohistiocytosis (HLH), and also suppresses metastasis in NSCLC models with high Rab1A expression. Itacitinib can be used for research on hemophagocytic lymphohistiocytosis and non-small cell lung cancer .
23
Research Areas:
Itacitinib adipate (INCB039110 adipate) is an orally active JAK1-selective inhibitor. Itacitinib adipate inhibits IFN-γ-mediated phosphorylation of STAT1 and downstream pro-inflammatory signaling pathways. Itacitinib adipate reduces the frequency and number of splenic neutrophils in mouse models, downregulates the levels of pro-inflammatory cytokines and chemokines, and inhibits pro-inflammatory gene expression pathways. Itacitinib adipate improves survival rate and clinical scores in mouse models of hemophagocytic lymphohistiocytosis (HLH), and also suppresses metastasis in NSCLC models with high Rab1A expression. Itacitinib adipate can be used for research on hemophagocytic lymphohistiocytosis and non-small cell lung cancer .
7
7 Cited Publications
Cat. No.: HY-135844
CAS No.: 1456891-34-1
Target:
Research Areas:
LS-102 is a selective E3 ubiquitin ligase synoviolin (Syvn1) inhibitor. LS-102 inhibits the autoubiquitination of synoviolin with an IC50 of 35 μM. LS-102 has the potential for rheumatoid arthritis treatment .
5
5 Cited Publications
Cat. No.: HY-N0401A
CAS No.: 81944-09-4
Category:
Natural Products Metabolic Disease Dicerothamnus rhinocerotis Plants Umbelliferae Disease Research Fields
Target:
2
1
1 Cited Publications
Target:
Research Areas:
ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile .
1
1 Cited Publications
Target:
Research Areas:
ASP-4058 hydrochloride is a next-generation, selective and orally active agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile .
Cat. No.: HY-N7364
CAS No.: 18794-84-8
Synonyms: trans-β-Farnesene
Category:
Infection Cannabis sativa L Terpenoids Sesquiterpenes Plants Moraceae Disease Research Fields
Target:
Cat. No.: HY-P990774
CAS No.: 2768386-15-6
Synonyms: ASP-7266; TRAB-1; UPB-101
Target:
Research Areas:
Cat. No.: HY-P991628
Synonyms: PF-08634404
Target:
Research Areas:
Cat. No.: HY-172435
CAS No.: 1431754-15-2
Synonyms: AGN-232411; AG-80308; AGN-411
Target:
Research Areas:
Rezuforimod (AGN-232411; AG-80308) is an ophthalmic solution targeting the formyl peptide receptor (FPR) pathway. Rezuforimod exerts anti-inflammatory effects by targeting the formyl peptide receptor pathway. Administered topically, Rezuforimod significantly reduces the corneal conjunctival staining score and improves ocular discomfort symptoms, with no serious adverse events reported and favorable overall safety profile. Rezuforimod shows remarkable potential to serve as a novel therapeutic option for dry eye disease .
Cat. No.: HY-B0426A
CAS No.: 140462-76-6
Synonyms: ALO4943A; KW4679
Category:
Alkaloids Other Alkaloids Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Inflammation/Immunology
Target:
Cat. No.: HY-W341625
CAS No.: 474943-80-1
Target:
Research Areas:
Trihexosylceramide (d18:1/12:0) is a glycosphingolipid and mood-related compound. Trihexosylceramide (d18:1/12:0) is characterized by elevated serum levels in Mus musculus fed a high-fat diet, and its levels are positively correlated with mood Z-scores. Accumulation of Trihexosylceramide (d18:1/12:0) in tissues is considered the etiology of angiokeratoma corporis diffusum. Trihexosylceramide (d18:1/12:0) can be used in studies related to high-fat diet-induced mood disorders .\n
Cat. No.: HY-W062109
CAS No.: 113806-05-6
Category:
Alkaloids Other Alkaloids Endogenous metabolite Disease Research Fields Inflammation/Immunology
Target:
Cat. No.: HY-P99883
CAS No.: 1399584-78-1
Synonyms: SAR156597
Target:
Research Areas:
Synonyms: U 74006F free base
Research Areas:
Tirilazad (U 74006F free base) is a neuroprotective agent. Tirilazad can also bind tightly to the main protease of the COVID-19 virus and exert anti-SARS-CoV-2 activity. Tirilazad scavenges hydroxyl and lipid peroxyl free radicals and maintains the levels of endogenous antioxidants. Tirilazad reduces cerebral infarct volume and improves neurobehavioral scores in animal models of focal ischemia. Tirilazad can be used in research related to ischemic stroke and subarachnoid hemorrhage .
Cat. No.: HY-P2283
CAS No.: 186359-67-1
Target:
Research Areas:
Thymol iodide is an iodine derivative of thymol, serving as a mild preservative and fungicide. Thymol iodide is commonly used as an iodine source in the intensive culture of rotifers. Thymol iodide effectively enables Brachionus "Cayman" rotifers to reach iodine levels similar to those of copepods, and maintains a high iodine content during storage. After 28 days of intrapleural injection of Thymol iodide, it does not enhance the efficacy of inducing pleurodesis in rabbits, nor does it improve the efficacy of talc slurry pleurodesis .
Target:
Research Areas:
QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC50=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC50=9.85 nM，TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
